Article Impact Level: HIGH Data Quality: STRONG Summary of Journal of Internal Medicine https://doi.org/10.1111/joim.70039 Dr. Allyson K. Palmer et al.
Points
- Cellular senescence is a central, age-related contributor to the pathogenesis and progression of metabolic diseases.
- Senescent cells accumulate in metabolic tissues, disrupting function through their pro-inflammatory senescence-associated secretory phenotype.
- Senotherapeutics, including senolytics, senomorphics, and senosensitizers, are being developed to selectively target these cells.
- Preclinical studies show promise for senotherapeutics, but clinical translation requires addressing biomarker, heterogeneity, and safety challenges.
- Existing antidiabetic agents can modulate senescence, offering a unique translational opportunity for preventing age-related metabolic disorders.
Summary
Metabolic diseases, encompassing obesity, Type 2 diabetes, and metabolic syndrome, are globally prevalent and increasingly linked to cellular senescence as a central age-related pathogenic factor. Senescent cells accumulate in critical metabolic tissues, where their senescence-associated secretory phenotype (SASP)—a pro-inflammatory and fibrogenic secretome—disrupts normal tissue function. These SASP factors contribute to insulin resistance, chronic inflammation, and adverse tissue remodeling, thereby accelerating the progression and complications associated with metabolic disorders.
The recognition of cellular senescence’s pivotal role has spurred the development of senotherapeutics, a novel class of interventions designed to target these dysfunctional cells. This class includes senolytics, which selectively eliminate senescent cells; senomorphics, aimed at suppressing the detrimental SASP; and senosensitizers, which enhance the vulnerability of resistant senescent cells to clearance. While preclinical studies have demonstrated significant promise for these interventions in ameliorating metabolic dysfunction and complications, their translation into widespread clinical practice faces hurdles such as the identification of robust biomarkers, addressing senescent cell heterogeneity, and optimizing the timing and safety profiles of treatments.
Despite these challenges, the field is advancing rapidly, with a growing understanding that some existing antidiabetic agents can modulate key features of senescence. This provides a unique translational opportunity, suggesting that the prevention of age-related metabolic disorders might be achieved, at least in part, with therapies already available in routine clinical practice. The targeting of cellular senescence with senotherapeutics is poised to fundamentally reshape the prevention and treatment paradigms for age-related metabolic diseases, offering the potential to enhance healthspan and substantially reduce the burden of these conditions across the lifespan.
Link to the article: https://onlinelibrary.wiley.com/doi/10.1111/joim.70039
References
Palmer, A. K., Spinelli, R., Prata, L. G. L., Chaib, S., Suda, M., Tchkonia, T., Smith, U., & Kirkland, J. L. (2025). Senotherapeutics for metabolic disease and diabetic complications. Journal of Internal Medicine, joim.70039. https://doi.org/10.1111/joim.70039
